The Phase 2 protocol submission to the FDA in the coming weeks and initiation in 1Q27 are the next key catalysts. The delay from prior timelines may temper near-term enthusiasm, but the 12-month stability data provides incremental validation of the disease-modifying hypothesis. Monitor for FDA feedback on the Phase 2 design and any partnership developments.
Price Chart
Executive Summary
Gain Therapeutics presented Phase 1b open-label extension data for rexaceract (GT-02287) at the MDS Congress, showing MDS-UPDRS motor scores remained stable over 12 months in 12 evaluable Parkinson's disease patients, with no clinically meaningful disease progression and a favorable safety profile. The company plans to submit a Phase 2 protocol to the FDA in the coming weeks and initiate the Phase 2 trial in 1Q27, a delay from prior expectations. The data supports disease-modifying potential but comes from a small, open-label study with no placebo control, limiting interpretability.
Key Facts
- 12 of 13 evaluable patients completed 12 months of daily oral rexaceract in the open-label extension as of August 31, 2026
- MDS-UPDRS motor scores (Parts II and III) were stable over 12 months, with no clinically meaningful progression (a clinically meaningful change is ~6 points/year)
- No new safety signals; lower incidence of TEAEs in Part 2 (9-month OLE) vs Part 1 (initial 3-month administration)
- Company expects to submit a Phase 2 protocol to the FDA in the coming weeks and initiate Phase 2 in 1Q27
- Participants with both high and low baseline CSF GluSph levels showed stabilization of motor scores
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech
Risk Factors
- Small sample size (12 evaluable patients) and open-label design limit statistical reliability and placebo comparison
- Phase 2 initiation delayed to 1Q27, indicating potential protocol or regulatory hurdles
- No revenue or near-term commercialization; company is pre-revenue and dependent on financing
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373017 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.15 (−33.14%) |
Oct 1, 2026 25d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.15 (−33.14%) |
Aug 11, 2026 10w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.15 (−44.17%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.15 (−30.72%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.15 (−43.35%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.15 (−43.35%) |
May 26, 2026 21w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.15 (−36.81%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.15 (−36.81%) |
Apr 28, 2026 25w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.15 (−34.66%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.15 (−39.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers